1. Search Result
Search Result
Results for "

B7

" in MedChemExpress (MCE) Product Catalog:

90

Inhibitors & Agonists

5

Peptides

44

Inhibitory Antibodies

13

Natural
Products

136

Recombinant Proteins

4

Isotope-Labeled Compounds

27

Antibodies

8

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-102090

    CD28 Inflammation/Immunology
    B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC50 of 50 nM .
    B7/CD28 interaction inhibitor 1
  • HY-B0511
    Biotin
    Maximum Cited Publications
    15 Publications Verification

    Vitamin B7; Vitamin H; D-Biotin

    Endogenous Metabolite Metabolic Disease
    Biotin, vitamin B7 and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .
    Biotin
  • HY-B0511R

    Vitamin B7 (Standard); Vitamin H (Standard); D-Biotin (Standard)

    Endogenous Metabolite Reference Standards Metabolic Disease
    Biotin (Standard) is the analytical standard of Biotin. Biotin, vitamin B7 and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .
    Biotin (Standard)
  • HY-P990279

    CD276/B7-H3 Apoptosis STAT Inflammation/Immunology Cancer
    Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .
    Anti-Mouse CD276/B7-H3 Antibody (MJ18)
  • HY-P10728

    RXFP Receptor Cardiovascular Disease Inflammation/Immunology
    B7-33 is a single-chain relaxin mimetic. B7-33 is a selective relaxin receptor 1 (RXFP1) agonist. B7-33 binds to RXFP1 and preferentially activates thepERK pathway over cAMP in cells (with RXFP1 expression). B7-33 is an anti-fibrotic agent. B7-33 has cardioprotective effects .
    B7-33
  • HY-P10325

    Vasopressin Receptor Oxytocin Receptor Cardiovascular Disease
    Kalata B7 is a cyclotide that can be isolated from Oldenlandia affinis DC (Rubiaceae) and possesses membrane-permeating capabilities. Kalata B7 is also a partial agonist of oxytocin and vasopressin V1a receptors .
    Kalata B7
  • HY-N13987

    Antibiotic Bacterial Infection
    Arylomycin B7 is a lipohexapeptide antibiotic against Gram-positive bacteria .
    Arylomycin B7
  • HY-B0511A

    Vitamin B7 sodium; Vitamin H sodium; D-Biotin sodium

    Endogenous Metabolite Metabolic Disease
    Biotin (Vitamin B7) sodium is a water-soluble B vitamin and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin sodium is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .
    Biotin sodium
  • HY-P990340

    CD276/B7-H3 Inflammation/Immunology
    Anti-B7-H3/CD276 Antibody is a CHO-expressed human antibody targeting B7-H3/CD276. Anti-B7-H3/CD276 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-B7-H3/CD276 Antibody
  • HY-P990170

    Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse PD-L2/B7-DC Antibody (TY25) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse PD-L2/B7-DC. Anti-Mouse PD-L2/B7-DC Antibody (TY25) blocks PD-L2 binding to PD-1 and blocks PD-1 signaling. Anti-Mouse PD-L2/B7-DC Antibody (TY25) can be used for the researches of inflammation and immunology, such as conjunctivitis and transplantation .
    Anti-Mouse PD-L2/B7-DC Antibody (TY25)
  • HY-P990114

    PD-1/PD-L1 Others
    Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine PD-L1/B7-H1 IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .
    Anti-Canine PD-L1/B7-H1 Antibody (JC071)
  • HY-P990127

    Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD80/B7-1 Antibody (RM80) is an anti-mouse CD80/B7-1 IgG2a monoclonal antibody. Anti-Mouse CD80/B7-1 Antibody (RM80) can inhibit the number of tissue-resident memory (TRM) cells. Anti-Mouse CD80/B7-1 Antibody (RM80) can prolong the survival time of transplants combined with CD86 mAb. Anti-Mouse CD80/B7-1 Antibody (RM80) can be used for research on inflammation conditions and immunology such as viral myocarditis and corneal transplant .
    Anti-Mouse CD80/B7-1 Antibody (RM80)
  • HY-P990128

    CD28 Inflammation/Immunology Cancer
    Anti-Rat CD80/B7-1 Antibody (3H5) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to rat CD80/B7-1. Anti-Rat CD80/B7-1 Antibody (3H5) blocks a costimulatory signals for T-cell activation. Anti-Rat CD80/B7-1 Antibody (3H5) can be used for the researches of cancer and immunology .
    Anti-Rat CD80/B7-1 Antibody (3H5)
  • HY-P990260

    Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD86/B7-2 Antibody (GL-1) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD86/B7-2. Anti-Mouse CD86/B7-2 Antibody (GL-1) can be used for the researches of inflammation and immunology, such as allergic pulmonary inflammation .
    Anti-Mouse CD86/B7-2 Antibody (GL-1)
  • HY-P99145

    PD-1/PD-L1 Cancer
    Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer .
    Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
  • HY-P9966

    MGA271

    CD276/B7-H3 Cancer
    Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
    Enoblituzumab
  • HY-B0511S3

    Vitamin B7-13C5; Vitamin H-13C5; D-Biotin-13C5

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Biotin- 13C5 (Vitamin B7- 13C5) is 13C labeled Biotin. Biotin, vitamin B7 and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids .
    Biotin-13C5
  • HY-P99367

    CD3 Inflammation/Immunology Cancer
    Ifinatamab is monoclonal immunoglobulin G1-kappa with anti-human B7 homolog 3 protein (Human B7-H3). Ifinatamab is a glycoforme α immunomodulateur .
    Ifinatamab
  • HY-P99762
    Obrindatamab
    1 Publications Verification

    MGD009

    CD3 Cancer
    Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
    Obrindatamab
  • HY-P990171

    PD-1/PD-L1 Cancer
    Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.
    Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)
  • HY-P99145A

    PD-1/PD-L1 Cancer
    Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) contains no Fc mutations just as the original rat IgG2b antibody does not. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) can be used for the research of cancer.
    Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1)
  • HY-P990172

    PD-1/PD-L1 Cancer
    Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.
    Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)
  • HY-171689

    AZD 8205

    Antibody-Drug Conjugates (ADCs) Cancer
    Puxitatug samrotecan (AZD8205) is an antibody-drug conjugate (ADC) targeting B7-H4. Puxitatug samrotecan is composed of the Puxitatug (HY-P990059) antibody targeting B7-H4, randomly conjugated to the Puxitatug samrotecan drug-linker (HY-163487) by reducing inter-chain cysteines. Puxitatug samrotecan has anti-tumor activity and can be used in the study of cancers expressing B7-H4 .
    Puxitatug samrotecan
  • HY-P990059

    INT-016

    CD276/B7-H3 Cancer
    Puxitatug is an immunoglobulin G1-κ, anti-[Homo sapiens VTCN1 (Vset domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)] Homo sapiens monoclonal antibody .
    Puxitatug
  • HY-N14191

    Antibiotic Bacterial Fungal Infection
    Malonylniphimycin is a macrolide antibiotic found in Streptomyces str. hygroscopicus B-7. Malonylniphimycin is resistant to Gram-positive bacteria, fungi and yeasts .
    Malonylniphimycin
  • HY-P991223

    Transmembrane Glycoprotein TNF Receptor Cancer
    NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
    NC762
  • HY-P991092

    EGFR CD276/B7-H3 Cancer
    IBI-334 is a bispecific B7-H3 and EGFR antibody. IBI-334 has an EGFR arm for signal blockage and is coupled with a fine-tuned B7-H3 arm with optimal affinity and binding domain. IBI-334 is afucosylated to enhance its antibody-mediated cell cytotoxicity (ADCC) effects. IBI-334 has a wide range of applications in many EGFR-driven solid tumors .
    IBI-334
  • HY-P991355

    PD-1/PD-L1 Cancer
    PDL-GEX is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. PDL-GEX can be used in cancer research .
    PDL-GEX
  • HY-P991356

    LAE-005

    PD-1/PD-L1 Cancer
    FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .
    FAZ-053
  • HY-P990014

    IMC-001; STI-3031

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
    Danburstotug
  • HY-P991357

    PD-1/PD-L1 Cancer
    STT-001 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. STT-001 can be used in Solid tumours research .
    STT-001
  • HY-P99157

    CD276/B7-H3 Cancer
    Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
    Omburtamab
  • HY-P3371

    DS-7300a; MABX-9001a

    Antibody-Drug Conjugates (ADCs) Cancer
    Ifinatamab deruxtecan (DS-7300a) is an ADC that binds an anti-B7-H3 antibody to the DNA topoisomerase I inhibitory anti-tumor drug DXd. Ifinatamab deruxtecan has antitumor activity .
    Ifinatamab deruxtecan
  • HY-P991421

    VISTA Cancer
    W0180 is a human IgG1 monoclonal antibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research .
    W0180
  • HY-155747

    Autophagy Akt mTOR Cancer
    FDW028 a potent and highly selective FUT8 inhibitor. FUT8 exhibits potent anti-tumor activity by defucosylation and impelling lysosomal degradation of B7-H3 through the chaperone-mediated autophagy (CMA) pathway. FDW028 can be used for metastatic colorectal cancer (mCRC) research .
    FDW028
  • HY-P991449

    PD-1/PD-L1 Tim3 Cancer
    LY3415244 is a human bispecific antibody (bsAb) targeting B7-H1/PD-L1/CD274 & TIM-3/HAVCR2/CD366. LY3415244 can be used in advanced solid tumors research .
    LY3415244
  • HY-P991537

    GSK5764227

    Antibody-Drug Conjugates (ADCs) CD276/B7-H3 Cancer
    HS-20093 Antibody is an antibody-drug conjugate (ADC) targeting B7-H3. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors .
    HS-20093 Antibody
  • HY-P99101

    AEX-4089

    ADC Antibody Cancer
    Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
    Vobramitamab
  • HY-P991354

    PD-1/PD-L1 Cancer
    GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .
    GR-1405
  • HY-P990623

    BMS-936559

    PD-1/PD-L1 Inflammation/Immunology
    MDX-1105 is a human antibody expressed in CHO that targets B7-H1/PD-L1/CD274. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    MDX-1105
  • HY-P99740

    CD276/B7-H3 ADC Antibody Cancer
    Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
    Mirzotamab
  • HY-148696A

    ADC Payload Topoisomerase Cancer
    Gly-Cyclopropane-Exatecan involves in the synthesis of anti-B7-H4 ADC, containing Exatecan (HY-13631), a DNA Topoisomerase I inhibitor. Gly-Cyclopropane-Exatecan participated in the formation of the ADC hu2F7-Exatecan (compound 34), which showed antitumor activity in vivo and in vitro .
    Gly-Cyclopropane-Exatecan
  • HY-118700

    Guanidinobiotin

    NO Synthase Neurological Disease
    2-Iminobiotin (Guanidinobiotin) is a biotin (vitamin H or B7) analog. 2-Iminobiotin is a reversible nitric oxide synthases inhibitor with Kis of 21.8 and 37.5μM for murine iNOS and rat n-cNOS, respectively . 2-Iminobiotin superimposes on hypothermia protects human neuronal cells from hypoxia-induced cell damage .
    2-Iminobiotin
  • HY-118700A

    Guanidinobiotin hydrobromide

    NO Synthase Neurological Disease
    2-Iminobiotin hydrobromide (Guanidinobiotin hydrobromide) is a biotin (vitamin H or B7) analog. 2-Iminobiotin hydrobromide is a reversible nitric oxide synthases inhibitor with Kis of 21.8 and 37.5 μM for murine iNOS and rat n-cNOS, respectively . 2-Iminobiotin hydrobromide superimposes on hypothermia protects human neuronal cells from hypoxia-induced cell damage .
    2-Iminobiotin hydrobromide
  • HY-P1698

    AB-103

    Bacterial CD28 Infection Inflammation/Immunology Cancer
    Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod
  • HY-P1698B

    AB-103 TFA

    Bacterial CD28 Infection Inflammation/Immunology Cancer
    Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod TFA
  • HY-P991447

    VISTA Cancer
    Anti-VSIR/VISTA Antibody (SG7) is a human monoclonal antibody (mAb) targeting VISTA/B7-H5. Anti-VSIR/VISTA Antibody (SG7) inhibits VISTA function and prevents PSGL-1 and VSIG3 from binding to VISTA. Anti-VSIR/VISTA Antibody (SG7) has anti-tumor activity in the mouse B16F10 melanoma model. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Anti-VSIR/VISTA Antibody (SG7)
  • HY-P99132
    Anti-Mouse CTLA-4 Antibody (9D9)
    1 Publications Verification

    CTLA-4 Inflammation/Immunology Cancer
    Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by regulating the ratio of CD8 + T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .
    Anti-Mouse CTLA-4 Antibody (9D9)
  • HY-B0511S

    Vitamin B7 d2-1; Vitamin H d2-1; D-Biotin d2-1

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Biotin-d2-1 is the deuterium labeled Biotin. Biotin is an enzyme co-factor present in minute amounts in every living cell.
    Biotin-d2-1
  • HY-119361

    (Rac)-Deoxysappanone B 7,4' dimethyl ether

    Microtubule/Tubulin Cancer
    (Rac)-Deox B 7,4, a homoisoflavanoid compound, inhibits microtubule polymerization via binding near the colchicine site and promote reversible G2 arrest. (Rac)-Deox B 7,4 possesses nanomolar anti-leukemic activity .
    (Rac)-Deox B 7,4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: